BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
NCT00346255
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
BB-10901
Sponsor
ImmunoGen, Inc.